바이오스펙테이터

by Naeun Bong

“… We intend to provide the clinical doctors with services that could enable them to make quick, accurate, and pertinent diagnoses of diseases within a week by exploiting Artificial intelligence(AI) and the database of genomics comprising 200-300 neonatal rare diseases with corresponding therapies for newborn babies admitted to the NICU …”

President Kang Sang-gu, who founded MedySapiens in 2016, introduced its core platform enabled to facilitate the diagnosis of more than 200 rare genetic diseases as in the above statement. MedySapiens devised the diagnosis-assisting service, enabling clinical doctors to make quick, accurate, and definite diagnosis, by delivering the results of the analysis on actionable genes associated with 200 or more specified diseases within a week through exploiting single examination on a small amount of blood sample of neonates.

Three Differentiable Points in Diagnosis of ‘Rare Genetic Diseases’ of MedySapiens

MedySapiens currently promotes the business of diagnosis-assisting service manifested in three differentiable points by reflecting the highly expensive therapeutic agents and waiting time of approximately two to four weeks to the availability of results of diagnosis.

Point ①The Design of NICU Panel

Above all, MedySapiens collaborated with faculties in the Department of Pediatrics in Seoul National University Hospital, and designed the NICU Panel, ‘MedyCVi’, capable of screening, detecting, and analyzing genes associated with more than 200 kinds of diseases of higher prevalence.

Point ② The Application of AI Technology

MedySapiens applied the AI technology enabling the spontaneous assessment of pathogenicity of genetic mutation detected by the ‘MedyCVi’. Based on scores set by MedySapiens, the AI can distinguish genetic mutations into categories of VUS (variant of uncertain significance), benign, or pathogenic, etc.

Point ③ ‘Web’ based Cloud

MedySapiens elaborated the MedyCVi in the form of a Web-based cloud other than the ‘Linux’ system to improve the availability and convenience of users (clinical doctors). Thus, MedyCVi’s contribution to the development of the database, resulting from the convenient use and management of clinical doctors, was realized.

100% Accuracy in Analysis Achieved in the First and Second Pilot Studies ... “Prospective Study Plans Are Prepared for New Patients”

MedySapiens managed the two pilot studies with the support from the Ministry of SMEs and Startups by exploiting the samples of patients admitted to the NICU in Seoul National University Hospital. The pilot tests were the blind tests designed to compare diagnoses with the results of diagnosis prepared by applying the NICU panel. MedySapiens accomplished 100% accuracy in the two pilot studies. Based on results obtained from the two pilot studies, MedySapiens intends to promote the prospective studies to be conducted in Seoul National University Hospital, Seoul National University Hospital in Bundang, Asan Medical Center, and Soonchunhyang University Hospital with new patients admitted to the NICU in each hospital. The practical objective of MedySapiens will be to make inroads into the American market. Since its founding in 2016, MedySapiens has maintained the relationship with a large General Hospital in California, USA, continuously, anticipating for the day of entering the American market,

‘Cardiovascular Analysis’, the First Mission of AI Technology ... Followed by the Smart Beauty and Smart Technology of Diagnosis Which Are in Progress

MedySapiens also collaborated with the Department of Cardiology of Asan Medical Center in Seoul as the first project using AI Technology supported by the Ministry of SMEs and Startups for the study of analyzing cardiovascular diseases only with X-ray images. In the project, AI technology is supposed to detect lesions of cardiovascular diseases from the X-ray images and evaluate the resulting risks quantitatively. Besides, MedySapiens currently manages the ‘Smart Beauty’ project based on AI technology also supported by the Ministry of SMEs and Startups wherein the assessment of skin is matched to customized and corresponding cosmetic products. The project, ‘Smart Technology of Diagnosis’, capable of diagnosing diseases through exploiting the AI technology, will be launched in the future with the completion of digitalization of pathologic organs.